Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Bullboard (NDAQ:PMN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by goldtechon Jan 03, 2025 10:56am

RE:RE:ARIA-E

Phase 1A was to identify any side effects in healthy patients, 1B will be infusing patients with Alzheimer's. If we do not remove monomers or placque and show specificity without any Aria , then ...more  
112
Discussion
Comment by Hafnesson Jan 02, 2025 8:01pm

RE:ARIA-E

I thought aria-e was ruled out in phase 1-a safety data?
66
Discussion
Post by goldtechon Jan 02, 2025 6:55pm

ARIA-E

If Brain bleeding is to be identified it will happen earl, my guess is 60 days and 2 dosing events. If we have no ARIA-E then we will have to measure the toxic oligomers and the cognition scale. If ...more  
172
Discussion
Comment by Blueknowser1on Jan 02, 2025 9:15am

RE:RE:Anticipation in the air, 2025 will be epic

on the precipice of becoming a leader in Alzheimers treatment.  Such a tragic disease, I hope Promis' drug is successful treating what has become one of the foremost problems with an aging ...more  
104
Discussion
Comment by Blueknowser1on Jan 01, 2025 12:58pm

RE:Anticipation in the air, 2025 will be epic

I like your attitude!  Although the market is so huge, other drugs that would help improve the problems associated with dementia and Alzheimers,etc., are welcome! I have been following Promis ...more  
131
Discussion
Post by Gbathaton Dec 31, 2024 1:34pm

Anticipation in the air, 2025 will be epic

As we end another year, patiently and not-so-patiently waiting for PMN310 to progress, there is optimism for ProMIS Neurosciences on the horizon. Unfortunately for patients, numerous competitors have ...more  
184
Discussion
Post by Gbathaton Dec 30, 2024 7:37pm

$30B Alz therapeutic market by 2033

Alzheimer’s Disease Therapeutics Market Value to Reach USD 30.8 Billion by 2033 | Driven by the Advancements in Neurological Research HUUUUUUGE
97
Comment by Gbathaton Dec 29, 2024 5:50pm

RE:RE:RE:PMN310 Phase 1b

I share your optimism on PMN310. I've been trying to keep an eye on the competition as well.  Alz 801 was supposed to have topline results from their Phase 3 in Q3 of 2024, per  https:/ ...more  
133
Discussion
Comment by bball67on Dec 29, 2024 3:54pm

RE:RE:PMN310 Phase 1b

Good news for shareholders , bad news for toxic oligomers, good news for non placebo trial patients. How about a little PMN310 to make the Alzheimer's go away. It worked in mice and monkeys. Seven ...more  
131
Discussion
Comment by Gbathaton Dec 27, 2024 7:00pm

RE:PMN310 Phase 1b

Great news indeed!  Let's goooooo!  Woot!    Glad I chose to buy more!  They stuck to their target!  Thanks to the team at PMN for working hard into the holiday ...more  
120
Discussion
Post by Speyeder999on Dec 27, 2024 9:55am

PMN310 Phase 1b

Great news! looks like Promis kept their promise! Good luck to all, first and foremost to the patients involved in the trials! https://clinicaltrials.gov/study/NCT06750432?intr=PMN310&rank=2
133
Discussion
Comment by Hafnesson Dec 26, 2024 9:11am

RE:RE:Charles Schwab putting hold on Pmn

I emailed them and the COO responded and said the same thing. Regardless, this is a barrier to buying. Trading as a penny stock is not good. It would seem more people would find interest in the ...more  
108
Discussion
Post by Gbathaton Dec 23, 2024 11:35am

$ABOS dragging too

$ABOS spiraling too.  Acumen's market cap is only $110M... crazy thing is they have $250M cash position as of mid November. https://finance.yahoo.com/news/acumen-pharmaceuticals-inc-abos-q3 ...more  
126
Comment by Gbathaton Dec 19, 2024 7:37pm

RE:Charles Schwab putting hold on Pmn

Only for unsettled funds.  Tell your friend to bid at $1 and it should go through at ask or lower.
99
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next